AstraZeneca has signed a five-year licensing deal with Moderna Therapeutics, a US biotechnology company specialising in drugs using RNA therapeutics.
Pharmaceutical companies Bayer, Intendis and Intraserv have filed a patent infringement lawsuit against Glenmark after it applied to market a generic version of rosacea treatment Finacea.
Generic drug maker Mylan has struck a deal with pharma companies Shionogi and Andrx to resolve a patent dispute over their diabetes drug Fortamet.
Janssen Products, a subsidiary of Johnson & Johnson, has sued Indian pharmaceutical company Hetero Drugs for applying to market a generic version of its HIV treatment Prezista.
Recent CJEU judgements on the interpretation of SPC regulations are not clear and have left judges frustrated, said Huw Evans, partner at Norton Rose LLP, at the 1st Annual Life Sciences Law Forum in London.
Day two of the 1st Annual Life Sciences Forum in London saw panellists discuss the European Unitary Patent and the Unified Patent Court.
Law firm Maurice Blackburn revealed on Monday that it will appeal against an Australian court decision that backed Myriad Genetics’ ownership of a human gene mutation linked to breast cancer.
India’s patent authorities have dealt a blow to German pharma company Bayer by refusing to overturn an order forcing the company to license one of its patented drugs.
ViiV Healthcare, a public health joint venture between GlaxoSmithKline, Shionogi and Pfizer, has signed up to the Medicines Patent Pool (MPP) to provide greater access to affordable AIDS treatments in developing countries.
The UK government announced a change to the Patent Act on Tuesday that will allow parties to run drug trials without infringing other parties’ patents.